tbuckley/cabot-search huggingface dataset:
RARE-43. PRIMARY CENTRAL NERVOUS SYSTEM EWING SARCOMA: A SINGLE INSTITUTION EXPERIENCE
Authors: Florencia Yorio, Lucas Alessandro, Naomi Arakaki, Nicolas Palomar, Alejandro Muggeri, Blanca Diez
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Ewing Sarcoma (ES) is defined by molecular markers, being t(11,22) the most frequent. Intracranial ES/pPNET usually represent metastases from extracranial sites. Primary Central Nervous System (CNS) lesions are extremely rare. MATERIAL AND METHODS Retrospective review of clinical records from patients with primary CNS ES/pPNET assessed at a neurological center in Argentina between 2007–2019. All confirmed with molecular marker. Clinical characteristics, imaging, histopathology, and treatment response were evaluated. Extensive workup included whole-body CT scan, skeletal-scintigraphy, and positron-emission tomography, excluding extracranial primary lesions in all cases. RESULTS Total 24p. Median age 22yo (2–65); M:F 2:1. Clinical presentation: intracranial hypertension, focal neurological deficit or seizures. In brain MRI 11 supratentorial lesions, 7 infratentorial and 6 diffuse leptomeningeal. Histopathology: diffuse pattern with small round blue cells 13/24p, other patterns were also described. CD99 marked positive in all cases and T(11.22) confirmed as well: 22 PCR and 2 FISH for EWSR1-rearrangement. Misdiagnosis lead to median delay for accuracy of 7,5mo (0–124); including other CNS primary tumors (n= 13), infectious diseases (n= 5) and other diagnoses (n= 4). Most patients (n= 10) were treated with Euro99-protocol (6 cycles plus local radiotherapy (RT)), 4 with Temozolomide, Irinotecan plus RT, 7 with other regimens and 2 received no treatment. Mean overall survival (OS): 58mo (0–132) and progression-free survival 22mo (0–85). Five year OS:41%. CONCLUSION Clinical behavior in primary CNS ES deferred from extraosseous ES, being necessary to apply a specific regimen for this pathology as there is no standard regime for intracranial ES/pPNET. Results showed two different groups of patients with long and very short survival. Presentation, histology, and outcomes are so uneven that we propose if a more specific molecular classification should be necessary. This is, to our knowledge, the largest case series reported describing a heterogeneous group despite the presence of accurate molecular diagnosis.
Oral rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine
Authors: Lucas McCarthy
Journal: Annals of Internal Medicine (2019)

ACP Journal Club19 November 2019Oral rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraineLucas McCarthy, MD, MSLucas McCarthy, MD, MSVirginia Mason Medical Center, Seattle, Washington, USA (L.M.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ201911190-059 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142-9. https://pubmed.ncbi.nlm.nih.gov/31291516Clinical Impact RatingsGIM/FP/GP: Neurology: References1 Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-58. [PMID: 12383060] Google Scholar2 Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114-25. [PMID: 23965396] Google Scholar3 Deen M, Correnti E, Kamm K, et al; European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18:96. [PMID: 28948500] Google Scholar Author, Article, and Disclosure InformationAffiliations: Virginia Mason Medical Center, Seattle, Washington, USA (L.M.)This article was published at Annals.org on 5 November 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOrally disintegrating rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine Lucas McCarthy Metrics 19 November 2019Volume 171, Issue 10Page: JC59KeywordsAdverse eventsCalcitoninMigraineNauseaNumber needed to treatPhase 2 trialsProtease inhibitorsSafetySerious adverse eventsVasodilation ePublished: 19 November 2019 Issue Published: 19 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Pan-genome cfDNA methylation analysis of metastatic prostate cancer
Authors: A. Wu, P. Cremaschi, D. Wetterskog, V. Conteduca, G.M. Franceschini, E. Gonzalez-Billalebeita, U.D. Giorgi, F. Demichelis, S. Lise, G. Attard
Journal: Annals of Oncology (2019)
Prevalence of the Antiphospholipid Antibodies in Young Adults with Ischemic Stroke
Authors: Antonella Vaccarino, Maria Pagliaro, Clara Rollone, Fabio Melis, Federica De Marco, Katia Savio, Marilena Guido, Mario Bazzan, Daniele Imperiale, Massimo Pini
Journal: Blood (2019)
Temporal ultrasound for monitoring tocilizumab treatment in giant cell arteritis: seeing beyond serum markers?
Authors: Gerasimos Evangelatos, George E Fragoulis, Alexios Iliopoulos
Journal: Annals of the Rheumatic Diseases (2019)

We read with great interest the letter of Nannini et al , which addressed the issue of treatment interruption in giant cell arteritis (GCA) patients treated with tocilizumab (TCZ) and the use of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) for disease monitoring and relapse predicting.1 In this study, FDG-PET examination after 2 months of TCZ discontinuation (14 months after treatment initiation) could identify those large-vessel GCA (LV-GCA) patients who would experience a relapse later, despite having normal inflammation markers. Interestingly, FDG-PET findings after 6 months of TCZ therapy were not significantly improved in patients who relapsed after TCZ discontinuation, in contrast to what was observed for those who maintained remission.1 According to authors, this imaging modality could be a useful monitoring and prognostic tool for patients with LV-GCA.

GCA, a type of large-size and medium-size vessel vasculitis, usually affects people over 50 years old. Two subtypes have been identified; namely cranial GCA and LV-GCA. Over the last years, ultrasound (US) of temporal arteries has been increasingly recognised as a first-line diagnostic tool for cranial GCA, while magnetic-resonance angiography and …
Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients
Authors: Olga A. Gavrilina, Elena N. Parovichnikova, Vera V. Troitskaya, Irina V. Galtseva, Galina A. Baskhaeva, Tatiana N. Obukhova, Julia O. Davydova, Andrey N. Sokolov, Ksenija I. Zarubina, Kamil D Kaplanov, Olga Samoilova, Pervin Zeinalova, Valery Lapin, Sergey N. Bondarenko, Elena Borisenkova, Tatiana Konstantinova, Elena E. Zinina, Maria Grishunina, Julia A. Chabaeva, Sergei M. Kulikov, Valery G. Savchenko, Elena Fokina
Journal: Blood (2019)
Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant
Authors: M Hasib Sidiqi, Abdullah S. S. Al Saleh, Iuliana Vaxman, Angela Dispenzieri, Francis K. Buadi, Eli Muchtar, Rahma M Warsame, Martha Q. Lacy, David Dingli, Nelson Leung, Wilson I Gonsalves, Prashant Kapoor, Taxiarchis Kourelis, S. Vincent Rajkumar, Shaji K. Kumar, Morie A Gertz
Journal: Blood (2019)
Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake
Authors: Alice Fletcher, Martin L. Read, Caitlin E.M. Thornton, Dean P. Larner, Vikki L. Poole, Katie Brookes, Hannah R. Nieto, Mohammed Alshahrani, Rebecca J. Thompson, Gareth G. Lavery, Iñigo Landa, James A. Fagin, Moray J. Campbell, Kristien Boelaert, Andrew S. Turnell, Vicki E. Smith, Christopher J. McCabe
Journal: Cancer Research (2019)

Abstract The sodium iodide symporter (NIS) is required for iodide uptake, which facilitates thyroid hormone biosynthesis. NIS has been exploited for over 75 years in ablative radioiodine (RAI) treatment of thyroid cancer, where its ability to transport radioisotopes depends on its localization to the plasma membrane. The advent of NIS-based in vivo imaging and theranostic strategies in other malignancies and disease modalities has recently increased the clinical importance of NIS. However, NIS trafficking remains ill-defined. Here, we used tandem mass spectrometry followed by coimmunoprecipitation and proximity ligation assays to identify and validate two key nodes—ADP-ribosylation factor 4 (ARF4) and valosin-containing protein (VCP)—controlling NIS trafficking. Using cell-surface biotinylation assays and highly inclined and laminated optical sheet microscopy, we demonstrated that ARF4 enhanced NIS vesicular trafficking from the Golgi to the plasma membrane, whereas VCP—a principal component of endoplasmic reticulum (ER)–associated degradation—governed NIS proteolysis. Gene expression analysis indicated VCP expression was particularly induced in aggressive thyroid cancers and in patients who had poorer outcomes following RAI treatment. Two repurposed FDA-approved VCP inhibitors abrogated VCP-mediated repression of NIS function, resulting in significantly increased NIS at the cell-surface and markedly increased RAI uptake in mouse and human thyroid models. Collectively, these discoveries delineate NIS trafficking and highlight the new possibility of systemically enhancing RAI therapy in patients using FDA-approved drugs. Significance: These findings show that ARF4 and VCP are involved in NIS trafficking to the plasma membrane and highlight the possible therapeutic role of VCP inhibitors in enhancing radioiodine effectiveness in radioiodine-refractory thyroid cancer.
Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy
Authors: Mark C. Walters, John F. Tisdale, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Markus Y. Mapara, Manfred Schmidt, Alexandra L. Miller, Francis J. Pierciey, Wenmei Huang, Jean-Antoine Ribeil, Julie Kanter, Alexis A. Thompson
Journal: Blood (2019)
NIMG-55. TO ASSESS THE UTILITY OF ADVANCED QUANTITATIVE DIFFUSION MRI DERIVED FROM MULTI B VALUE ACQUISITIONS IN THE ASSESSMENT OF TREATMENT RESPONSE, USING A SPATIALLY-INDEPENDENT APPROACH
Authors: Shah Islam, Melanie Morrison, Adam Waldman
Journal: Neuro-Oncology (2019)

Abstract PURPOSE To assess the utility of advanced diffusion MRI derived from multi b value acquisitions in the assessment of treatment response, using a spatially-independent approach. METHOD AND MATERIALS 13 GBM patients were enrolled into our multicentre study. All patients completed RT with TMZ. Imaging was performed pre-RT and mid RT. The MRI protocol included a ‘low’ b value acquisition (b= 0s/mm, 50s/mm, 150s/mm, 200s/mm, 500s/mm, 1000s/mm) from which monoexponential diffusion indices ADC and biexponential indices, IVIM parameters D*, D and f were calculated. A ‘high b value’ acquisition (b=0 s/mm, 500s/mm, 1000s/mm, 1500s/mm, 2000s/mm, 2500s/mm, 3000s/mm, 3500s/mm, 4000s/mm) was acquired to allow stretched exponential diffusion indices, DDC and alpha to be derived. FLAIR sequences were used to define ROI and clinical assessment of mid-treatment and end-treatment response using RANO criteria. Histograms were generated from voxels located within manually segmented ROIs defined by increased signal on T2 FLAIR images. Changes in histogram percentile profiles were evaluated across the two timepoints and compared with RANO assessment at the mid treatment and end treatment timepoints. RESULTS Following completion of treatment, 5 patients had PD, 4 SD and 4 CR. Patients with PD showed a histogram shift to the left across all diffusion models, in keeping with increasing diffusion restriction and implying increased cellularity. Patients with SD or CR showed little or no shift in the histogram. DDC and f are the most predictive of progression against RANO assessment, and appear superior to routine ADC. Reduction in 75th centile (f) and 95th centile (DDC) are the most sensitive histogram metrics for predicting early progressive disease. CONCLUSION Results suggest association between early changes in specific diffusion components and subsequent treatment response. Spatially-independent diffusion parameter comparisons provide unbiased sampling of tumour heterogeneity and abrogate the confound of voxel-to-voxel misregistration due to tumour growth/shrinkage.
1. Prophylaxis in Surgery
Authors: O STORM
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents
Authors: Michael A Spinner, Alexey Aleshin, Marianne A Santaguida, Steven A Schaffert, Taher Abbasi, Jeffrey N Sanders, A Scott Patterson, Diane Heiser, James L Zehnder, Peter L Greenberg
Journal: Blood (2019)
A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)
Authors: Sarit Assouline, Amitkumar Mehta, Paolo F Caimi, Bingxia Wang, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim
Journal: Blood (2019)
Interferon-Gamma Impairs Expansion and Hematopoietic Support of Bone Marrow Mesenchymal Stromal Cells
Authors: Marieke Goedhart, Anne Cornelissen, Carlijn Kuijk, Sulima Geerman, Fernanda Pascutti, Marion Kleijer, Jaap van Buul, Stephan Huveneers, Howard Young, Carlijn Voermans, Martijn Nolte
Journal: Blood (2016)
Dangerous Anaesthetic Device
Authors: T. H. Howells
Journal: BMJ (1964)

MEDIBSH 1659 intercostal muscles to provide either an adequate cough mechanism or augmented res- piratory excursion.(2) In cases of cord section between C.2 and C.6, upper trapezius fibres to operate voluntary finger flexion.In cases in which shoulder girdle and arm muscles have been spared but hand function is deficient, it is hoped that this defect may thus be remedied on a controlled voluntary basis.(3) Ultimately perhaps, by cross over from anterior deltoid fibres to hip flexors of oppo- site side, to provide a method of walking.-Iam, etc.,
Coronary Microvascular Dysfunction Is Associated With Myocardial Ischemia and Abnormal Coronary Perfusion During Exercise
Authors: Haseeb Rahman, Matthew Ryan, Matthew Lumley, Bhavik Modi, Hannah McConkey, Howard Ellis, Cian Scannell, Brian Clapp, Michael Marber, Andrew Webb, Amedeo Chiribiri, Divaka Perera
Journal: Circulation (2019)

Coronary microvascular dysfunction (MVD) is defined by impaired flow augmentation in response to a pharmacological vasodilator in the presence of nonobstructive coronary artery disease. It is unknown whether diminished coronary vasodilator response correlates with abnormal exercise physiology or inducible myocardial ischemia.
Peripheral Blood Cytopenia and Subsequent Risk of Cardiovascular Disease and Mortality
Authors: Radhika Gangaraju, Insu Koh, Marguerite R. Irvin, Leslie A. Lange, Damon E. Houghton, Diego A Herrera, Monika Safford, Mary Cushman, Smita Bhatia, Neil A. Zakai
Journal: Blood (2019)
Detection of Immunoglobulin Heavy Chain Gene Clonality By High-Throughput Sequencing for Minimal Residual Disease Monitoring in Chronic Lymphocytic Leukaemia
Authors: Alicia Serrano, Azahara Fuentes, Blanca Ferrer Lores, Veronica Lendinez, Carolina Monzo, Carmen Ivorra, Macarena Ortiz, María-Dolores García-Malo, Rosa Collado, Maria Jose Lys, Mar Tormo, Maria Jose Terol, Blanca Navarro, Javier F Chaves
Journal: Blood (2019)
Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg
Authors: Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv, Ewa Wasik-Szczepanek, Ozren Jaksic, Mihnea Zdrenghea, Uri Greenbaum, Inga Mandac, Martin Simkovic, Marta Morawska, Ohad Benjamini, Martin Spacek, Anatoly Nemets, Osnat Bairey, Andrea Visentin, Rosa Ruchlemer, Luca Laurenti, Oana Stanca Ciocan, Michael Doubek, Lev Shvidel, Nagib Deli, Fatima Miras Calvo, Anne De Meûter, Maria Dimou, Francesca Romana Mauro, Marta Coscia, Horia Bumbea, Szász Róbert, Tamar Tadmor, Odit Gutwein, Massimo Gentile, Lydia Scarfo, Alessandra Tedeschi, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, Sarit Assouline, Maria Papaioannou, Andrei Breaster, Luciano Levato, Michael Gregor, Gian Matteo Rigolin, Javier Loscertales, Angeles Medina Perez, Marten R. Nijziel, Viola Maria Popov, Rosa Collado, Irma Slavutsky, Shai Levi, Aaron Polliack, Paolo Ghia
Journal: Blood (2019)
Inhibition of De Novo Pyrimidine Nucleotide Synthesis By the Novel DHODH Inhibitor PTC299 Induces Differentiation and/or Death of AML Cells
Authors: Marla Weetall, Kensuke Kojima, Sujan Piya, Christopher Trotta, John Baird, Kylie O'Keefe, Bansri Furia, Gautam M. Borthakur, Robert Spiegel
Journal: Blood (2019)
The Prognostic Significance of ASXL1/EZH2 Co-Mutation in Comparison with ASXL1 or EZH2 Mutation Alone in Myelodysplastic Syndromes
Authors: Pukhraz Basra, David Gajzer, Mohammad O Hussaini, Hailing Zhang, Lynn C. Moscinski, Eric Padron, David A Sallman, Rami S. Komrokji, Ling Zhang, Jinming Song
Journal: Blood (2019)
PATH-10. RELATIONSHIP BETWEEN CYTOGENETIC COMPLEXITY AND PERITUMORAL EDEMA IN HIGH-GRADE ASTROCYTOMA
Authors: Kyoung Su Sung, Young-Jin Song, Jin-Yeong Han, Ki-Uk Kim
Journal: Neuro-Oncology (2019)

Abstract The purpose of the study is to reveal the association of cytogenetic complexity and peritumoral edema volume (PTEV) and its prognostic significance in high-grade astrocytoma patients by culturing patient tumor cells. Twenty-seven high-grade astrocytoma patients were divided into three groups according to karyotype complexity: normal, non-complex karyotype (NCK), and complex karyotype (CK). Endothelial growth factor receptor (EGFR) amplification was detected by FISH, and its association with chromosome 7 abnormalities was analyzed. Mean PTEV of each group was compared by ANOVA to evaluate the relationship between PTEV and cytogenetic complexity. The PTEV of patients in normal (n=6), NCK (n=8), and CK (n=13) groups were 24.52±17.73, 34.26±35.04, and 86.31±48.7 cm3, respectively (P=0.005). Ten out of 11 patients with EGFR amplification showed abnormalities in chromosome 7. The mean PTEV of EGFR-amplified and non-amplified groups were 80.4±53.7 and 41.3±37.9 cm3, respectively (P=0.035). The average survival of patients with PTEV less than 90 cm3 was 30.52±26.11 months, while in patients with PTEVs over or equal to 90 cm3, it was 10.83±5.53 months (P=0.007). The results show an association of complex karyotype with the PTEV of high-grade astrocytoma. EGFR amplification plays a significant role in the formation of peritumoral edema, causing PTEV to increase, which is related with survival. This implies that cytogenetic karyotype can be applied as a prognostic factor.
A randomized controlled trial of online symptom searching to inform patient generated differential diagnoses
Authors: Seth S. Martin, Emmanuel Quaye, Sarah Schultz, Oluwaseun E. Fashanu, Jane Wang, Mustapha O. Saheed, None Prem Ramaswami, Hermes de Freitas, Berthier Ribeiro-Neto, Kapil Parakh
Journal: npj Digital Medicine (2019)

Abstract Patient online health searching is now commonplace, however, the accuracy of patient generated differentials for new symptoms and potential for patient anxiety are concerns. We aimed primarily to determine the accuracy of patient generated differentials for new symptoms with and without online searching, and secondarily, to evaluate the impact of searching on anxiety levels. In the waiting room prior to seeing a clinician, 300 patients with new symptoms were randomly assigned 1:1:1 to Google searching with health related features including a symptom search tool vs Google searching with health related features disabled vs no searching. Participants were 18 years or older and presenting to the emergency department of an urban academic medical center with new low-acuity symptoms that were not due to exacerbation of a chronic condition. Search groups received access on a tablet/smartphone to Google searching with or without health related features. Both search groups could access any websites; health related features led the patient to common diagnoses and physician-validated information. The primary outcome was accuracy of the patient generated differential assessed by matching at least two of the top three diagnoses on the clinician’s differential. A secondary outcome was anxiety by a visual analogue scale. Patients were a median of 33.1 (IQI 26.2–45.9) years old, 60% women, 63% black, 82% had a high school education or less, and 45.7% reported having performed an online search prior to presentation. Search group patients spent a median of 3.82 (2.53–5.72) minutes searching online. Similar proportions of patients in each group matched at least two of three clinician diagnoses: 27.0% and 28.3% for Google searching with and without health related features vs 23.8% in the no search group. Patients in the search groups had a similar odds of matching ≥2/3 diagnoses as the no search group [OR (95% CI): 1.23 (0.70–2.13), p = 0.47]. Anxiety was unchanged with online searching. In conclusion, brief online searching in the waiting room did not improve accuracy of patient generated differential diagnoses for new symptoms. The absence of an increase in patient anxiety provides reassurance for subsequent work to refine and investigate online symptom search tools.
Trends, Predictors and Outcomes of Portal Vein Thrombosis in Hospitalized Pancreatic Cancer Patients: National Inpatient Sample Analysis 1998-2016
Authors: Hussam Alhasson, Peng Cai, Zimu Gong, Anas Saad, Muneer Al-Husseini, Pei Yang, Yu Zhao
Journal: Blood (2019)